Recombinant JAK2 (532-1132, V617F) Protein

• Description:

  Recombinant JAK2 (532-1132, V617F) Protein_x000D_ Catalog number: B2017614_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 10 µg_x000D_ Molecular Weight or Concentration: 71.1 kDa_x000D_ Supplied as: SOLUTION_x000D_ Applications: a molecular tool for various biochemical applications_x000D_ Storage: -80°C_x000D_ Keywords: Janus Kinase 2, Tyrosine-Protein Kinase JAK2, EC 2.7.10, JTK10_x000D_ Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ References:_x000D_ 1: Vekariya U, Toma M, Nieborowska-Skorska M, Le BV, Caron MC, Kukuyan AM, Sullivan-Reed K, Podszywalow-Bartnicka P, Chitrala KN, Atkins J, Drzewiecka M, Feng W, Chan J, Chatla S, Golovine K, Jelinek J, Sliwinski T, Ghosh J, Matlawska-Wasowska K, Chandramouly G, Nejati R, Wasik M, Sykes SM, Piwocka K, Hadzijusufovic E, Valent P, Pomerantz RT, Morton G, Childers W, Zhao H, Paietta EM, Levine RL, Tallman MS, Fernandez HF, Litzow MR, Gupta GP, Masson JY, Skorski T. DNA polymerase θ protects leukemia cells from metabolically induced DNA damage Blood. 2023 May 11;141(19):2372-2389._x000D_ 2: Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC. A gain-of-function mutation of JAK2 in myeloproliferative disorders N Engl J Med. 2005 Apr 28;352(17):1779-90._x000D_ 3: Skoda RC. Thrombocytosis Hematology Am Soc Hematol Educ Program. 2009:159-67._x000D_ 4: Li Z, Xing S, Wang S, Ho WT, Zhao ZJ. Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity Exp Hematol. 2007 Nov;35(11):1624-32._x000D_ 5: Usart M, Stetka J, Luque Paz D, Hansen N, Kimmerlin Q, Almeida Fonseca T, Lock M, Kubovcakova L, Karjalainen R, Hao-Shen H, Börsch A, El Taher A, Schulz J, Leroux JC, Dirnhofer S, Skoda RC. Loss of Dnmt3a increases self-renewal and resistance to pegIFN-α in JAK2-V617F-positive myeloproliferative neoplasms Blood. 2024 Jun 13;143(24):2490-2503._x000D_ 6: Virtanen AT, Haikarainen T, Sampathkumar P, Palmroth M, Liukkonen S, Liu J, Nekhotiaeva N, Hubbard SR, Silvennoinen O. Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain Pharmaceuticals (Basel). 2023 Jan 4;16(1):75._x000D_ 7: Tiedt R, Hao-Shen H, Sobas MA, Looser R, Dirnhofer S, Schwaller J, Skoda RC. Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice Blood. 2008 Apr 15;111(8):3931-40._x000D_ 8: Gnanasambandan K, Magis A, Sayeski PP. The constitutive activation of Jak2-V617F is mediated by a π stacking mechanism involving phenylalanines 595 and 617 Biochemistry. 2010 Nov 23;49(46):9972-84._x000D_ 9: Abe M, Funakoshi-Tago M, Tago K, Kamishimoto J, Aizu-Yokota E, Sonoda Y, Kasahara T. The polycythemia vera-associated Jak2 V617F mutant induces tumorigenesis in nude mice Int Immunopharmacol. 2009 Jul;9(7-8):870-7._x000D_ 10: Stein BL, Williams DM, Wang NY, Rogers O, Isaacs MA, Pemmaraju N, Spivak JL, Moliterno AR. Sex differences in the JAK2 V617F allele burden in chronic myeloproliferative disorders Haematologica. 2010 Jul;95(7):1090-7. _x000D_ _x000D_ Products Related to Recombinant JAK2 (532-1132, V617F) Protein can be found at Proteins

• Short Description:

  Catalog Number: B2017614 (10 µg)

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height:

  0.5

• Height :

  0.5

• CAS Number:

  9000-83-3